Comparative Pharmacology
Head-to-head clinical analysis: ALPROSTADIL versus LATANOPROST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPROSTADIL versus LATANOPROST.
ALPROSTADIL vs LATANOPROST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular cAMP, and relaxing smooth muscle. It also inhibits platelet aggregation.
Latanoprost is a prostaglandin F2α analogue that acts as a selective FP receptor agonist. It increases uveoscleral outflow of aqueous humor by binding to prostanoid FP receptors in the ciliary muscle, leading to matrix metalloproteinase activation and remodeling of the extracellular matrix, thereby reducing intraocular pressure.
Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.
Instill one drop (1.5 mcg) of 0.005% ophthalmic solution into the affected eye(s) once daily in the evening.
None Documented
None Documented
Clinical Note
moderateLatanoprost + Unoprostone
"Latanoprost may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateLatanoprost + Hydrochlorothiazide
"Latanoprost may increase the hypotensive activities of Hydrochlorothiazide."
Clinical Note
moderateTiaprofenic acid + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Latanoprostene bunod
5-10 minutes; rapidly metabolized in the lungs, clinical effect lasts longer due to continuous infusion.
Terminal half-life of latanoprost acid is 17 minutes (0.28 hours) systemically; clinically, intraocular pressure reduction persists for 24 hours due to prolonged receptor binding.
Primarily via urine (90%) as metabolites; 10% unchanged; minimal fecal excretion.
Renal: 88% (metabolites); fecal: 6% (metabolites); unchanged latanoprost is not excreted renally.
Category C
Category A/B
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carprofen."